Filing summary
Entity and period: The supplied filing is Bioptix, Inc.’s Form 10-K for the fiscal year ended December 31, 2016—not a filing under the name Riot Platforms, Inc. It reports full-year results, not a standalone 2016 fourth quarter. Financial figures below are in U.S. dollars.
Business context and reporting period
Bioptix had historically pursued appendicitis diagnostics and licensed animal-health technology. In September 2016 it acquired BiOptix Diagnostics, Inc. (BDI), a developer of surface plasmon resonance research instruments, for 627,010 Bioptix shares valued at approximately $2.58 million. BDI was consolidated from September 12, 2016. The acquisition’s preliminary allocation included $2.0 million of identifiable intangible assets and $430,000 of goodwill.
On January 14, 2017, the company adopted a plan to exit BDI and reduce its workforce, after reassessing product-development needs, sales forecasts, and expected cash requirements. It said it was exploring strategic alternatives and potential buyers or partners for BDI and its legacy appendicitis assets. The Ceva animal-health license relationship continued.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Product sales | $9,416 | $101,388 |
| Animal-health license revenue recognized | $96,699 | $96,698 |
| Gross profit on product sales | $6,358; 68% margin | $70,802; 70% margin |
| SG&A | $5.55 million | $6.76 million |
| Research and development | $863,000 | $2.16 million |
| Operating loss | $6.31 million | $8.75 million |
| Net loss | $4.27 million; $1.05 per share | $8.76 million; $2.26 per share |
| Cash used in operating activities | $5.52 million | $6.87 million |
2016 net loss included a $1.94 million gain on the sale of the company’s former headquarters. Sales and cost of sales were very small; license revenue was recognized over time from the Ceva agreement. The reported product gross margin is based on those limited sales.
At December 31, 2016, cash and cash equivalents were $5.53 million and short-term investments were $7.51 million, totaling $13.04 million in cash and liquid investments. Working capital was $12.69 million, total assets were $17.04 million, total liabilities were $2.12 million, and stockholders’ equity was $14.92 million. Debt and other obligations were $139,611, all current; the property mortgage was paid off following the February 2016 property sale. The accumulated deficit was $109.86 million.
Cash increased by $3.52 million during 2016. Investing activities provided $9.35 million, including approximately $1.81 million net cash from the property sale and net proceeds from securities transactions; financing activities used $311,000 for debt repayments. Patent impairment charges were $535,000 in 2016 versus $188,000 in 2015. No income-tax benefit was recorded.
Material changes, outlook, and risks
- Sales fell from $101,388 to $9,416 as the business shifted away from APPY 1 sales and BDI contributed only from its September acquisition. R&D decreased 60% and SG&A decreased 18%, principally following suspension of appendicitis activities and the facility sale, partly offset by BDI costs.
- The 2016 facility sale generated a $1.94 million accounting gain and approximately $1.81 million in net cash after expenses and mortgage payoff.
- Management expected continuing operating losses and said working capital was expected to fund estimated cash needs through the first quarter of 2018, subject to strategic transactions. The filing also says the company was monitoring expenses and considering additional financing; there is no assurance financing or a strategic transaction would be obtained.
- The January 2017 BDI exit plan was expected to result in approximately $2.7 million of early-2017 charges: about $2.2 million for asset write-downs and $500,000 for wind-down, severance, and transaction costs. The appendicitis patents were deemed fully impaired at year-end; the filing reports related 2016 patent impairment expense of $535,000.
- In March 2017, the company reported private placements totaling $7.0 million: $2.25 million in common-stock units, of which $1.0 million had been released from escrow, and $4.75 million in convertible notes held in escrow pending release conditions. The notes and warrants were subject to financing terms, including shareholder-approval provisions; therefore, not all proceeds were available cash as described in the filing.
- Key risks include failure to find a strategic transaction or acceptable BDI disposition, further losses and cash depletion, potential financing dilution, inability to monetize legacy assets, and maintaining Nasdaq listing requirements. The company warned it might be unable to continue if it could not complete a suitable transaction. It reported no material off-balance-sheet arrangements.
- The company reported that disclosure controls and internal control over financial reporting were effective at year-end. The 2016 auditor gave an unqualified opinion on the 2016 financial statements; the filing explains that the 2015 comparative statements were not re-audited by that auditor as a whole.
Important facts for investors to verify
- Confirm the issuer identity and period: this is Bioptix’s FY2016 10-K, not a Riot Platforms filing or a Q4-only report.
- Check the subsequent filings for the actual completion and terms of the March 2017 financings, escrow releases, shareholder approvals, and resulting dilution.
- Verify the outcome and costs of the BDI wind-down or any asset sale, and compare actual charges with the $2.7 million estimate.
- Assess cash burn against the stated first-quarter 2018 runway estimate, including strategic, public-company, lease, and other commitments.
- Track whether Ceva advances the licensed animal-health products and whether milestone or royalty payments are realized; these amounts depend on future development, approvals, and sales.